He described studies showing that chemically degrading specific proteoglycans near areas of CNS injury can improve regeneration within the treated area. November s lecturer was Daniel Lammertse, M.D. , medical director of Craig Hospital in Colorado, and project director of the Rocky Mountain Spinal Cord Model System. Lammertse described the outlook of the SCI patients he has treated. His discussion included the ethics and pragmatics of SCI treatment, and emphasized the difference between statistical versus clinical significance. In reviewing past trials of drugs such as GM-1 and methylprednisolone, and of FES devices, he drew lessons about how future trials should be improved by better outcome measures and focus on the unique needs of SCI patients.
All contents are Copyrighted.